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ABSTRACT 
 
Erin Kyle Hudnall: The Effects of Oral Probiotic Supplements on the Human Gut 
Microbiome 
(Under the direction of Colin R. Jackson, Ph.D.) 
 
A diverse bacterial community makes up the human gut microbiome and is 
essential not only to digestion, but also to other physiological processes. This bacterial 
community is subject to change due to external factors including, but not limited to, age, 
diet, and lifestyle. This study observed the effects of oral probiotic supplements on this 
bacterial community. Fecal samples were collected from a single subject once each week 
during alternating two- to six-week cycles of taking and abstaining from the probiotic 
supplement. The samples were purified, the bacterial cells within lysed, and the enclosed 
DNA was collected. A portion of the 16S rRNA gene was amplified and sequenced. 
Sequences were identified and compared to determine whether there were measurable 
effects of taking the probiotic on the subject’s gut microbial community. Firmicutes and 
Bacteroidetes were the dominant bacterial Phyla, with smaller proportions of 
Proteobacteria and Actinobacteria. Fluctuations in the subject’s gut microbiome were 
seen at the phylum level and at multiple taxonomic levels within these phyla from the 
start to the end of the study, but did not generally correspond to cycles of taking the 
probiotic. Furthermore, the relative abundance of Bacillus coagulans, the bacterial 
species within the probiotic supplement, did not change dramatically. This study 
	 v	
showed that taking this particular probiotic supplement did not cause substantial changes 
in the relative abundances of bacterial taxonomic groups in the human gut, and that  the 
fluctuations seen were likely due to other factors – for example, normal and expected 
variations in the individual’s gut bacteria, intestinal permeability caused by the subject’s 
food allergies, or other external influences.  
	 vi	
TABLE OF CONTENTS 
 
LIST OF TABLES AND FIGURES…………………………………………………….vii 
INTRODUCTION…………………………………………………………………….…..1 
METHODS………………………………………………………………………………..6 
RESULTS………………………………………………………………………………..13 
DISCUSSION……………………………………………………………………………25 
LIST OF REFERENCES………………………………………………………………...29 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 vii	
LIST OF TABLES AND FIGURES 
 
Table 1 Schedule of fecal sample collection for the subject involved in the 
study.………………………………………………………………………8 
Table 2 Summary of the various commands within the software package, mothur, 
that were used to analyze data in this study, and their intended purpose for 
analysis..………………………………………………………………….12 
Figure 1 Image of an agarose gel demonstrating the presence of DNA isolated from 
representative stool samples……………………………………………..16 
Table 3 Bacterial community composition of fecal samples obtained from a human 
subject, prior to taking probiotic supplements…………………………...17  
Figure 2 Changes in the relative abundance of Phylum Firmicutes (a) and the 
families within Order Clostridia (part of Phylum Firmicutes; b) in bacterial 
communities in stool samples taken from an individual during cycles of 
abstaining from and taking a probiotic supplement……………………...18 
Figure 3 Changes in the relative abundance of Phylum Bacteroidetes in bacterial 
communities in stool samples taken from an individual during cycles of 
abstaining from and taking a probiotic supplement……………………...19 
	 viii	
Figure 4 Changes in the relative abundance of the species within Family 
Bacteroidaceae (Phylum Bacteroidetes). Percentages of an unclassified 
species (a), of Bacteroides caccae (b), of Bacteroides ovatus (c), and of 
Bacteroides fragilis (d) in bacterial communities in stool samples taken 
from an individual during cycles of abstaining from and taking a probiotic 
supplement……………………………………………………………….20 
Figure 5 Changes in the relative abundance of Phylum Proteobacteria (a), the 
Classes within the phylum (b), and the orders within one of those classes 
(Gammaproteobacteria; c) in bacterial communities in stool samples taken 
from an individual during cycles of abstaining from and taking a probiotic 
supplement……………………………………………………………….22 
Figure 6 Changes in the relative abundance of Phylum Actinobacteria (a) and the 
species within Order Bifidobacteriales (part of Phylum Actinobacteria; b) 
in bacterial communities in stool samples taken from an individual during 
cycles of abstaining from and taking a probiotic supplement……………23 
Table 4 Average percentage of Clostridia and of total bacteria made up of Bacillus 
coagulans in fecal samples obtained from a human subject, during 
alternating cycles “off” probiotic supplement and “on” probiotic 
supplement……………………………………………………………….24
	 1	
INTRODUCTION 
There are trillions of bacteria, representing more than a thousand species, living 
on and within the human body. It is estimated that bacterial cells out number human cells 
in the body by a factor of ten to one (Ackerman 2012). These bacteria perform many 
important functions in metabolism and defense (Hopkins et al. 2001). For example, 
bacteria typical of the ‘normal’ human intestinal community assist the body in metabolic, 
nutritional, and immunological functions including degradation of certain food 
components, production of vitamins, and production of certain digestive enzymes 
(Holzapfel et al. 1998). These bacteria exert crucial metabolic activities by fermenting 
non-digestible polysaccharides such as fibers and starches into energy substrates (short-
chain fatty acids) for the benefit of both the microbes themselves as well as the host 
(Blaser 2014). These metabolic activities also lead to the production of vitamin K, 
vitamin B12, folic acid, and amino acids, substances which humans are unable to produce 
themselves. In addition, the intestinal microbiome participates in defending the body 
against pathogens through colonization resistance, the production of antimicrobial 
compounds, and contributing to the mucosal immune system (Gerritsen et al. 2011). 
The large intestine is by far the most heavily colonized portion of the digestive 
tract, containing up to 10
12 bacterial cells per gram of gut contents (Gibson et al. 1995). 
The bacteria within the large intestine base their metabolism on the nutrients a person 
consumes, causing a diverse bacterial community to be present in this organ.  It is
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estimated that the large intestine of healthy adults is host to approximately 500 different 
species belonging to more than 190 genera (Ansell 2011). 
Bacterial communities in the human gut are predominately composed of members 
of Phylum Bacteroidetes, which typically account for 17-60% of identified sequences and 
Phylum Firmicutes, which account for approximately 35-80% (Shoaie et al. 2013). 
Phylum Bacteroidetes consists of four classes: Bacteroidia, Flavobacteria, 
Sphingobacteria, and Cytophagia (Thomas et al. 2011). These classes range in metabolic 
type from the strictly anaerobic Bacteroidia to the solely aerobic Flavobacteria (Thomas 
et al. 2011). Bacteroidia are the dominant class of Bacteroidetes found in the human large 
intestine, because their obligate anaerobic metabolism allows them to thrive in the 
oxygen-poor environmental conditions (Thomas et al. 2011).  
The other major phylum that dominates the human large intestinal community, 
Firmicutes, is currently the largest bacterial phylum, containing more than 200 genera. 
The majority of the Firmicutes detected in the human intestinal tract fall primarily into 
two groups, Clostridium coccoides (also known as Clostridium cluster XIVa) and 
Clostridium leptum (also known as Clostridium cluster IV). The bacterial species falling 
into each of these groups are obligate anaerobes capable of producing endospores  
(Gerritsen et al. 2011). A larger concentration of Firmicutes in the gut has been found to 
be associated with obesity. It is theorized that this correlation is due their production of 
excess energy from nutrients that have been consumed (Fujimura et al. 2010). Other 
important bacterial phyla in the human gut include the Actinobacteria (Fujimura et al. 
2010) and various Proteobacteria. Each of these organisms plays some role as part of the 
microbial community in the human large intestine (Shoaie et al. 2013). 
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The variable nature of gut bacteria allows individuals to be studied for differences 
and similarities on various levels such as age, geography, or diet. Diet and environmental 
factors begin to affect the gut microbial community beginning from birth. Vaginally 
delivered infants show higher levels of Bifidobacterium and Bacteroides while infants 
born via Cesarean section exhibited a gut microbial community dominated by 
Staphylococcus, Streptococcus, and Clostridium difficile (Fujimura et al. 2010). In one 
study, infants who were exclusively fed a formula diet showed a greater abundance of 
Clostridium difficile and Escherichia coli than those infants that were breastfed only. The 
two groups maintained similar abundances of Bifidobacteria; however, the breastfed 
infants showed greater gene expression within these Bifidobacteria, which may have 
allowed them to metabolize a greater variety of complex oligosaccharides (Fujimura et al. 
2010).  
External factors continue to contribute to the gut microbiota throughout human 
life. A change in diet at any time can result in changes in the relative abundances of 
major phyla of gut bacteria, which could lead to diseases such as obesity (Turnbaugh et 
al. 2009). The ratio of Firmicutes to Bacteroidetes in lean subjects (3:1) has been reported 
to be enhanced by a factor of ten in obese subjects (up to 35:1; Fujimura et al. 2010). 
While a higher ratio of Firmicutes to Bacteroidetes tends to be correlated with obesity 
(Fujimura et al. 2010), it may be that a decrease in the amount of Bacteroidetes, rather 
than an actual increase in Firmicutes, could be responsible for the increased ratio between 
these phyla in obese subjects (Armougom et al. 2009). Aging also plays a role in the 
variability of intestinal bacteria, causing structural changes in the microbiota. This 
process affects the proportion of protective Bifidobacteria (members of the 
	 4	
Actinobacteria; Garrity et al. 2004) leading to major effects on innate colonization 
resistance (Hopkins et al. 2001). Parameters, such as nutrient consumption or antibiotic 
use, can be manipulated for comparison among individuals or within a single individual. 
Analyzing the connection between gut bacteria and the human host has lead to 
discoveries that may further advances in human wellness (Kinross et al. 2011).  
Each bacterial species has a specific 16S rRNA gene sequence (Woese 1987). 
Modern approaches to microbial ecology rely on sequencing this variable region to 
identify the specific types of bacteria present and to estimate overall bacterial diversity 
(De Santis et al. 2006). The use of this 16S rRNA gene sequencing technique is important 
to the study of microbial diversity in the human gut, as this technique removes the need 
to culture bacteria in order to identify them. This aspect is particularly important because 
many of the intestinal bacteria, such as species of Class Bifidobacteria, are anaerobic and 
therefore difficult to culture using standard approaches (Turnbaugh et al. 2009). Thus, 
16S rRNA gene sequencing is a valuable tool for the identification and comparison of 
intestinal bacteria, allowing for diverse studies concerning the gut microbiome; next 
generation sequencing of regions of this gene have helped increase our knowledge of the 
gut microbial community over the last decade. 
In recent years, there has been interest in improving intestinal health and digestion 
by modulating the composition of the gut bacterial community through introduction of a 
potentially remedial community (Collins et al. 1999). Attempts have been made to 
modulate the indigenous intestinal microbiome through the ingestion of live microbial 
adjuncts, called ‘probiotics.’ Although various definitions have been proposed to describe 
these products, Havenaar et al. (1992) first suggested a definition according to which 
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probiotics are defined as “mono- or mixed cultures of live microorganisms which, when 
applied, beneficially affect the host by improving the properties of the indigenous 
microflora” (Holzapfel et al. 1998). The most widely used and accepted definition, 
however, describes probiotics as “live microbial food supplements that beneficially affect 
the host animal by improving its intestinal microbial balance” (Collins et al. 1999).  
These definitions encompass over-the-counter preparations that contain 
lyophilized bacteria for adult human use. The microorganisms included in these 
preparations are often lactic acid producers such as Lactobacilli and Bacilli (Phylum 
Firmicutes) as well as Bifidobacteria (Collins et al. 1999). Some of the most important 
functional effects of the bacterial species introduced into the gut through probiotic 
supplements include aspects such as immune modulation and strengthening the gut 
mucosal barrier (Holzapfel et al. 1998). An effective probiotic should meet certain 
criteria. These include exertion of a beneficial effect on the host, containing a large 
number of viable cells, and capability of surviving and metabolizing in the gut. In 
addition, probiotic supplements must remain viable during storage and use and be 
nonpathogenic and nontoxic (Collins et al. 1999). 
This study monitored the composition of the large intestinal bacterial community 
of a single individual in an attempt to determine the effects of consuming an over-the-
counter probiotic supplement on the gut microbiota. Stool samples were obtained once a 
week over a period of eight months, within which the subject alternated between 
approximately six-week “on” cycles of consuming the supplement and “off” cycles of 
abstaining. The gut microbiome composition was characterized by 16S rRNA gene 
sequencing, facilitating analysis of this diverse community. 
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METHODS 
 
Background Information 
 This study was conducted on a single subject – a 21-year-old female 
approximately 1.57 meters tall. The subject lives a lightly active lifestyle and has a diet 
limited by allergies, thus avoiding large quantities of wheat, rice, and soy. The 
commercial probiotic supplement taken was Schiff® Digestive Advantage® Probiotic 
Gummies, distributed by Reckitt Benckiser (Parsippany, New Jersey) which were 
acquired over-the-counter at a Wal-Mart store in Oxford, Mississippi, on March 18, 2015. 
The bacterial species contained in this supplement was listed to be Bacillus coagulans, 
with each gummy containing 250 million viable cells at the time of manufacture. The 
subject cycled through two- to six-week periods of consuming and abstaining from the 
supplement. During “on” cycles, the subject consumed the maximum dose (four 
gummies) each morning at approximately 9:00 AM.  
 
Sample Collection 
Stool samples (approximately 0.1 g) were collected from the subject each Sunday, 
beginning March 22 and ending November 29, 2015. Each sample was collected 
immediately following regular defecation using a sterile swab. In order to reduce possible 
contamination of the sample by bacteria on the skin, care was taken to avoid skin contact. 
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The sample was then aseptically transferred to a sterile collection tube, and immediately 
frozen (-20°C) and stored until all samples had been collected. 
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Table 1. Schedule of fecal sample collection for the subject involved in the study. For 
each sample, the distinction between “on” cycles of consuming probiotic supplements 
and “off” cycles of abstaining from the supplements is noted.  
 
Sample ID Date Cycle 
1 22-Mar Off 
2 29-Mar Off 
3 5-Apr Off 
4 12-Apr On 
5 19-Apr On 
6 26-Apr On 
7 3-May On 
8 10-May On 
9 17-May On 
10 24-May On 
11 31-May Off 
12 7-Jun Off 
13 9-Aug On 
14 16-Aug On 
15 23-Aug On 
16 30-Aug On 
17 6-Sep On 
18 13-Sep On 
19 20-Sep Off 
20 27-Sep Off 
21 4-Oct Off 
22 11-Oct Off 
23 18-Oct Off 
24 25-Oct Off 
25 1-Nov On 
26 8-Nov On 
27 15-Nov On 
28 22-Nov On 
29 29-Nov On 
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DNA Extraction 
Samples were allowed to thaw to room temperature. Bacterial DNA was then 
extracted from the samples using a Mo Bio PowerFecal™ DNA Isolation kit, following 
the detailed protocol provided by the manufacturer (Mo Bio Laboratories; Carlsbad, 
California), and described as follows. Thawed samples were loaded into tubes containing 
sterile garnet beads and a buffer solution to aide in dissolving and dispersing the sample 
particles during homogenization and cell lysis. Sodium dodecyl sulfate (SDS) was added 
to help break down fatty acids and lipids in bacterial cell membranes, and the tubes were 
heated at 65°C for 10 minutes. The tubes were then agitated for 10 minutes to cause the 
beads to collide with the cells and help lysis (“bead beating”). Tubes were then 
centrifuged and the supernatant retained and sequentially treated with proprietary 
inhibitor removers (Mo Bio Laboratories).  A high concentration salt solution was then 
added to the final DNA solution, which was then bound to a silica filter. The bound DNA 
was rinsed with ethanol to further remove impurities. A sterile elution buffer was then 
added to the filter to solubilize and release the bound DNA from the silica filter. The 
presence of DNA was verified by agarose gel electrophoresis (220 V, 25 minutes) and the 
purified DNA samples transferred to sterile tubes, and immediately frozen (-20°C) and 
stored until all samples were prepared for sequencing. 
 
DNA Sequencing 
 The hypervariable V4 region of the bacterial 16S rRNA was amplified and 
sequenced using paired-end, barcoded Illumina MiSeq next generation sequencing 
(Kozich et al. 2013). This sequencing procedure was conducted at the Molecular and 
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Genomics Core Facility at the University of Mississippi Medical Center (UMMC) in 
Jackson, MS. The resulting 16S rRNA sequence data were subsequently downloaded as 
FASTQ files and assessed via the bioinformatics software package, mothur (Schloss et al. 
2009) using the recommended procedures according to Schloss et al. (2011) and Kozich 
et al. (2013) as follows.  
Raw FASTQ data resulting from two separate reads (R1 and R2) during the 
sequencing process of each sample were merged to generate high quality sequence data. 
Multiple copies of identical unique sequences were consolidated to enable faster data 
processing. The sequences were then compared against pre-aligned reference sequences 
found in the SILVA database (Quast et al. 2013), and screened based on their length and 
on potential ambiguity between bases. This alignment process was used to account for 
potential gaps and obtain a better classification, verifying that the sequences were truly 
collected from a portion of the 16S rRNA gene. Sequences containing runs of greater 
than eight identical sequential bases were removed, as they could be indicators of 
potential sequencing error. Sequences differing by two or fewer bases were then clustered 
together to remove potential amplification artifacts, as these could represent noise from 
sequencing or PCR error rather than actual genetic variation. Chimeras	were	 checked	for	 and	 eliminated	 using	 the	 incorporated	 UCHIME	 software	 (Edgar	 et	 al.	 2011).	These	 are	 unreal	 sequences	 that	 originated	 from	more	 than	 one	 initial	 sequence,	having	been	combined	during	amplification	due	to	incomplete	extension	against	one	template	 then	 completion	 of	 the	 extension	 against	 a	 different	 template.	 The 
remaining sequences were then classified using the Greengenes database  (Desantis et al. 
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2006). Contaminant sequences – those from chloroplasts or mitochondria, for example – 
were removed from the dataset.  
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Table 2. Summary of the various commands within the software package, mothur, that 
were used to analyze data in this study, and their intended purpose for analysis. 
Command Function 
Make.contigs Initial Processing 
Screen.seqs Screen data for length errors 
Unique.seqs Filters out identical sequences to reduce processing time 
Count.seqs Compress unique sequences and samples together 
Align.seqs Aligns sequences to an established database 
Filter.seqs Filters out non-informative gaps 
Pre.cluster Clusters almost identical sequences together 
Chimera.uchime Identifies chimeras within sequences 
Remove.seqs Removes chimeras 
Classify.seqs Classifies remaining sequences according to GreenGenes 	
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RESULTS 
Stool samples were obtained and bacterial DNA extracted and analyzed according 
to the aforementioned procedures. The presence of DNA in select samples was verified 
via gel electrophoresis (Figure 1), and the samples proved suitable for 16S rRNA gene 
sequencing. Sequencing was successful and yielded a total of 539,134 valid bacterial 
sequences, which classified into 518 species belonging to 435 genera, across twenty-
seven samples. Prior to the addition of any probiotic supplement, Phylum Firmicutes 
dominated the dataset, accounting for 65.7% of the total sequences, followed by Phylum 
Bacteroidetes, accounting for 25.5%. Sequences identified as Proteobacteria and 
Actinobacteria were also fairly prevalent and represented 4.6% and 4.1% of the total 
number of sequences, respectively (Table 3). 
The overall percentages of Phylum Firmicutes showed a decreasing trend during 
each successive cycle of taking the probiotic supplement (Figure 2a); the mean 
percentage of Firmicutes to overall bacteria during the first “on” cycle was 59.5%, during 
the second was 45.4%, and was 21.2% during the third. Class Clostridia dominated this 
phylum, making up an average of 99.11% of the Firmicutes throughout all cycles. The 
order Clostridiales made up 100% of this class, and was made up of four families. Family 
Lachnospiraceae was the dominant family within the Clostridiales except for the sample 
taken on August 16, while Ruminococcaceae was the second most dominant family 
except for the same sample, within which the relative abundances of these two families 
were reversed. Family Veillonellaceae and an unclassified family also made up a small
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portion of this class (Figure 2b).  
The Bacteriodetes exhibited no major changes in their proportional abundance 
over the course of the study (Figure 3). The Bacteroidetes were dominated by Class 
Bacteroidia (99.7%), which was made up entirely of Order Bacteroidales, of which 
99.9% of the bacteria fell into Family Bacteroidaceae and 100% of those belonged to the 
genus Bacteroides. Four main species made up this genus – an unclassified species 
(Figure 4a), Bacteroides caccae (Figure 4b), Bacteroides ovatus (Figure 4c), and 
Bacteroides fragilis (Figure 4d). These species showed no major changes in relative 
abundance throughout any of the cycles.  
Phylum Proteobacteria showed a clear surge in their relative abundance during the 
final cycle of taking the probiotic supplement (Figure 5a). Three classes made up nearly 
the entirety of this phylum – Class Betaproteobacteria, Class Deltaproteobacteria, and 
Class Gammaproteobacteria. Betaproteobacteria dominated the phylum during the first 
and second “on” cycles, except for a dip on May 17, but showed a marked decrease 
during the third. The Deltaproteobacteria remained at a relatively stable, low level 
throughout the course of the study.  The Gammaproteobacteria were low during the first 
two “on” cycles, except for a spike on May 17, but showed a dramatic increase to 
dominate the phylum during the final cycle of taking the probiotic supplement (Figure 
5b). The three orders within Gammaproteobacteria were Order Enterobacteriales, 
composed entirely of Escherichia coli, Order Pasteurellales, composed of 93.0% 
Haemophilus parinfluenzae, and Order Pseudomonadales, made up 66.8% by an 
unclassified species belonging to the genus Pseudomonas and 33.2% by Acinetobacter 
guilloulae (Figure 5c). 
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Phylum Actinobacteria showed a possible slight decreasing trend in overall 
percentages with each successive cycle, but overall did not show a distinguishable trend 
based on the cycles (Figure 6a). The two major classes, Actinobacteria (93.53%) and 
Coriobacteria (6.47%), were slightly variable but again showed no trend based on the 
probiotic cycles. Within Class Actinobacteria the dominant order was Bifidobacteriales 
(96.5%), with 100% of the bacteria within falling into Family Bifidobacteriaceae, and 
100% of that family made up of the genus Bifidobacterium. An unclassified species 
dominated the genus at 94.99%, and the species Bifidobacterium bifidum made up 0.05%; 
among these species there was no distinguishable trend, save for a spike in 
Bifidobacterium bifidum in the November 22 sample (Figure 6b). 
During the “off” cycles of abstaining from the probiotic supplement, the species 
Bacillus coagulans made up 0.00% of the Clostridia and of the total gut bacteria, 
increasing slightly during the “on” cycles (Table 4). This species made up 92.39% of the 
bacterial sequences in the probiotic supplement, with the remaining portion composed of 
20 other sequence types; however, Bacillus coagulans was never very prevalent in the gut 
community. Overall, there was no clear distinction in the gut microbiome between cycles 
of taking and not taking the probiotic, and the specific bacteria within the probiotic never 
became dominant members of the gut bacterial community.  
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Figure 1. Image of an agarose gel demonstrating the presence of DNA isolated from 
representative stool samples (samples 5-12, noted by numbers above each lane).
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Table 3. Bacterial community composition of fecal samples obtained from a human 
subject, prior to taking probiotic supplements. Samples are listed by date (Day-Month 
2015). Numbers represent the number of sequences obtained that classified into that 
taxon, with corresponding percentages of the total from that sample below them.  
Taxon 22-March 29-March 5-April Mean 
Phylum Firmicutes 
9,043 11,771 10,864 10,559 
69.94% 69.05% 58.07% 65.7% 
Phylum Bacteroidetes 
3,066 3,663 5,856 4,195 
23.71% 21.49% 31.30% 25.5% 
Phylum Proteobacteria 
317 793 1275 795 
2.45% 4.65% 6.82% 4.6% 
Phylum Actinobacteria 
498 786 693 659 
3.85% 4.61% 3.70% 4.1% 
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Figure 2. Changes in the relative abundance of Phylum Firmicutes (a) and the families 
within Order Clostridiales (part of Phylum Firmicutes; b) in bacterial communities in 
stool samples taken from an individual during cycles of abstaining from (unshaded areas) 
and taking (shaded areas) a probiotic supplement. 
 
Percentages	of	Families	Within	Order	Clostridiales	
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Figure 3. Changes in the relative abundance of Phylum Bacteroidetes in bacterial 
communities in stool samples taken from an individual during cycles of abstaining from 
(unshaded areas) and taking (shaded areas) a probiotic supplement.	
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Figure 4. Changes in the relative abundance of the species within Family Bacteroidaceae 
(Phylum Bacteroidetes). Percentages of an unclassified species (a), of Bacteroides caccae 
(b), of Bacteroides ovatus (c), and of Bacteroides fragilis (d) in bacterial communities in 
stool samples taken from an individual during cycles of abstaining from (unshaded areas) 
and taking (shaded areas) a probiotic supplement. 
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Figure 5. Changes in the relative abundance of Phylum Proteobacteria (a), the Classes 
within the phylum (b), and the orders within one of those classes (Gammaproteobacteria; 
c) in bacterial communities in stool samples taken from an individual during cycles of 
abstaining from (unshaded areas) and taking (shaded areas) a probiotic supplement.	
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Figure 6. Changes in the relative abundance of Phylum Actinobacteria (a) and the species 
within Order Bifidobacteriales (part of Phylum Actinobacteria; b) in bacterial 
communities in stool samples taken from an individual during cycles of abstaining from 
(unshaded areas) and taking (shaded areas) a probiotic supplement.	
0	
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
22
-M
ar
	
29
-M
ar
	
5-
Ap
r	
12
-A
pr
	
19
-A
pr
	
26
-A
pr
	
3-
M
ay
	
10
-M
ay
	
17
-M
ay
	
24
-M
ay
	
31
-M
ay
	
7-
Ju
n	
14
-Ju
n	
21
-Ju
n	
28
-Ju
n	
5-
Ju
l	
12
-Ju
l	
19
-Ju
l	
26
-Ju
l	
2-
Au
g	
9-
Au
g	
16
-A
ug
	
23
-A
ug
	
30
-A
ug
	
6-
Se
p	
13
-S
ep
	
20
-S
ep
	
27
-S
ep
	
4-
O
ct
	
11
-O
ct
	
18
-O
ct
	
25
-O
ct
	
1-
N
ov
	
8-
N
ov
	
15
-N
ov
	
22
-N
ov
	
29
-N
ov
	
Pe
rc
en
ta
ge
	
Date	
Percentages	of	Phylum	Ac4nobacteria	
0	
20	
40	
60	
80	
100	
22
-M
ar
	
29
-M
ar
	
5-
Ap
r	
12
-A
pr
	
19
-A
pr
	
26
-A
pr
	
3-
M
ay
	
10
-M
ay
	
17
-M
ay
	
24
-M
ay
	
31
-M
ay
	
7-
Ju
n	
14
-Ju
n	
21
-Ju
n	
28
-Ju
n	
5-
Ju
l	
12
-Ju
l	
19
-Ju
l	
26
-Ju
l	
2-
Au
g	
9-
Au
g	
16
-A
ug
	
23
-A
ug
	
30
-A
ug
	
6-
Se
p	
13
-S
ep
	
20
-S
ep
	
27
-S
ep
	
4-
O
ct
	
11
-O
ct
	
18
-O
ct
	
25
-O
ct
	
1-
No
v	
8-
No
v	
15
-N
ov
	
22
-N
ov
	
29
-N
ov
	
Pe
rc
en
ta
ge
	
Date	
Percentages	of	Species	Within	Order	Biﬁdobacteriales	
Biﬁdobacterium	biﬁdum	 Biﬁdobacterium	unclassiﬁed	
(a)	
(b)	
	 24	
Table 4. Average percentage of Clostridia and of total bacteria made up of Bacillus 
coagulans in fecal samples obtained from a human subject, during alternating cycles 
“off” (unshaded areas) probiotic supplement and “on” (shaded areas) probiotic 
supplement. Samples are listed by their Sample ID.  
 
Cycle Percentage of Bacillus coagulans in Clostridia 
Percentage of Bacillus 
coagulans in total Bacteria 
Samples 1-3 0.000% 0.0000% 
Samples 4-10 0.030% 0.0002% 
Samples 11-12 0.000% 0.0000% 
Samples 13-18 0.001% 0.0000% 
Samples 19-24 0.00% 0.0000% 
Samples 25-29 0.025% 0.0001% 
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DISCUSSION 
This study examined the effects of an over-the-counter probiotic supplement on 
the human gut microbiome. A total of twenty-nine samples were taken over 
approximately six-week cycles “on” and “off” the supplement. For twenty-seven of these 
samples, 16S rRNA sequencing was used to determine the bacterial taxa present and their 
relative proportions; the remaining two samples were unsuitable for analysis, possibly 
due to low DNA yield from the extraction procedure. This data suggested that changes in 
the gut bacterial community did indeed occur, however, these changes were not 
immediately attributable to the use of the probiotic supplement. Fluctuations in the 
relative abundances of different bacterial populations were expected, although it was 
uncertain which taxa would be affected, and at what taxonomic levels the fluctuations 
would be seen. It was expected that samples taken during the “on” cycles would differ 
from those taken during the “off” cycles, and that the changes in abundances would 
follow a trend throughout the course of the study. To some extent, this was the case for 
certain bacterial phyla and for various taxa within these phyla; however, fluctuations did 
not occur in the proportions of Bacillus coagulans, the live species contained within the 
probiotic supplement. It is quite possible that the changes seen were due to expected 
variability in gut bacteria or to other external factors, such as those attributable to the 
subject’s food allergies.  
Sequences classified as members of Phyla Firmicutes and Bacteroidetes were 
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dominant within the samples, followed by sequences identified as Proteobacteria and 
Actinobacteria. Bacteroidetes are commonly found in the human gut, and may be 
important in digestion as well as interacting with the immune system to limit pathogenic 
colonization of the gut (Thomas et al. 2011). This phylum is known for its symbiotic 
activity in degrading biopolymers and polysaccharides in the large intestine (Mahowald 
et al. 2009, Thomas et al. 2011). Members of Firmicutes are also common with the gut; 
these bacteria are Gram-positive, sometimes anaerobic bacteria. The most prevalent 
sequences were identified as being in the Class Clostridia, genus Faecalibacterium. The 
large representation of this typical intestinal genus supports that the samples included 
only intestinal bacteria not those bacteria present on skin of the anus (Miquel et al. 2013). 
Sequences identified as being in Phyla Proteobacteria and Actinobacteria were prevalent 
in smaller proportions. Specifically, one species of Proteobacteria found in every sample 
was Escherichia coli. Because E. coli are well adapted to the conditions of the human 
large intestine and well documented as occurring within (Rajilic-Stojanovic et al. 2007), 
the presence of this species also supports correct sampling and handling.  
Many previous studies have found that diet and other factors affect gut microbe 
composition (Muegge et al. 2011, Wu et al. 2011, David et al. 2014).  Distribution 
between and within the major phyla for the particular community studied was likely 
affected by the restrictive nature of the subject’s diet due to allergy limitations on 
consumption of common dietary staples wheat, rice, and soy. The lining of a normal 
intestinal tract is nearly leak proof and only fully digested food molecules are permitted 
to pass through this lining into the bloodstream and lymph vessels. However, this leak 
proof lining is only one cell layer thick and can be easily damaged as its cells have a short 
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life span, extremely high metabolic activity, and intense nutritional demands. Damage to 
the intestinal lining is detrimental, as the intestines are full of hostile digestive enzymes 
and trillions of microorganisms that would cause irritation if allowed to escape into the 
bloodstream. If the diet does not contain enough nutrients – as is the case of those with 
certain food allergies – to repair the intestinal permeability, it can become a persistent 
problem. This permeability, often termed “Leaky Gut Syndrome,” can also be due to 
inflammation of the lining that occurs when an allergen is inadvertently ingested 
(Brodhead 2002). A combination of the usually expected variability in gut bacteria and a 
leaky gut is the most probable cause of the relative changes in abundances of gut 
bacterial taxa observed in this study.  
Findings of a connection between food allergies and intestinal permeability have 
provided the foundation for various intervention studies designed to modify gut microbial 
composition for the treatment of allergic disease and for aiding digestion. These studies 
were based on the speculation that the flora within probiotic supplements would aid in 
digestion, generate important nutrients, stimulate the immune system, and diminish 
allergic reactivity, thus diminishing the effects of intestinal permeability. Studies have 
shown that breastfed infants have higher amounts of Bifidobacteria in their gut; further 
research now suggests that children with adequate quantities of Bifidobacteria are less 
likely to develop allergic diseases. Bifidobacteria are commomly included in probiotic 
supplements. A strain taken from Swiss cheese, Propionibacterium freudenreichii, 
stimulates the growth of various strains of Bifidobacteria, and also shows promise for 
delivery through oral supplements (Brodhead 2002). Lactobacillus rhamnosus is another 
species that contains some of the most impressive strains of scientifically 
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validated probiotics and can markedly diminish symptoms in those with food allergies 
(Brodhead 2002). 
The effects of a variety of other beneficial bacteria in probiotic supplements have 
been studied, but more stringent causality assessments should be applied to demonstrate 
the consistency of the assumed linkage between the gut microbiome and allergies (Yao et 
al. 2010). Because little to no detectable increase in Bacillus coagulans was seen 
throughout any of the cycles of supplementing with that species, this study determined 
that the use of this particular probiotic supplement is not likely to increase the proportion 
of Bacillus coagulans within the gut. Further studies may reveal, however, that by 
introducing this species, other taxa are enabled to increase or caused to decrease within 
the microbial community. Relative abundances of bacteria at various taxonomic levels 
showed both positive and negative fluctuations. While possible explanations for these 
changes were outlined above, the specific reasons are outside the scope of this study. 
Further work could be done to determine whether normal and expected variations in the 
individual’s gut bacteria, a leaky gut caused by the subject’s food allergies, or other 
external factors caused these fluctuations or whether the introduction of Bacillus 
coagulans by means of the supplement indeed caused a “domino effect” on other taxa 
within the gut community. 
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